IGF-1 LR3 (1 mg Vial) Dosage Protocol
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with extended half-life (~6 hours vs ~12 minutes for native IGF-1) due to substitution at position 3 (Glu→Arg) and an N-terminal 13-amino-acid extension.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. This schedule uses the maximum practical dilution (3.0 mL) for clear measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not shake.
- Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
- Label the vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Follow a validated product-specific use-by period; aliquoting or freezing does not establish an extended use-by without stability data.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (IGF-1 LR3, 1 mg each) | 8 weeks: 3 vials (~2.24 mg total) 12 weeks: 4 vials (~3.64 mg total) 16 weeks: 6 vials (~5.04 mg total) |
| Insulin Syringes (U-100, 0.5 mL or 1 mL) | 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL, 1 bottle 12 weeks (4 vials): 12 mL, 2 bottles 16 weeks (6 vials): 18 mL, 2 bottles |
| Alcohol Swabs | 8 weeks: 112 swabs, 2 boxes 12 weeks: 168 swabs, 2 boxes 16 weeks: 224 swabs, 3 boxes |
Safe disposal: Place used needles and syringes in a puncture-resistant sharps container.
Protocol Overview
This makes effects faster than HGH (days vs weeks) but with hypoglycemia risk that requires careful management.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
IGF-1 LR3 is a 83-amino-acid analog of IGF-1 with an arginine substitution at position 3 (reducing IGFBP binding) and an N-terminal 13-amino-acid extension. Both modifications extend half-life and increase free IGF-1 bioactivity.
It binds the IGF-1 receptor producing tyrosine kinase signaling that drives cellular proliferation, protein synthesis, and inhibition of apoptosis. Effects include skeletal muscle hypertrophy, hyperplasia, and metabolic shifts.
Potential Benefits & Side Effects
Potential Benefits
- Promotes skeletal muscle hypertrophy in animal and human studies.
- Anabolic effects more rapid than HGH due to direct IGF-1R activation.
- Studied in muscle-wasting conditions.
- Reduced binding to IGFBPs increases bioavailability.
Side Effect Profile
- Hypoglycemia risk — IGF-1 has insulin-like glucose-lowering effects.
- Joint pain in some users.
- Theoretical malignancy promotion concerns at supraphysiologic IGF-1.
- Tissue overgrowth at very high doses.
Lifestyle Factors
- Eat carbohydrate within 30 minutes of dosing to manage hypoglycemia risk.
- Resistance training maximizes anabolic outcomes.
- Monitor blood glucose, especially when starting.
- Adequate protein supports protein-synthesis substrate availability.
Injection Technique
- Subcutaneous into abdomen or thigh, or intramuscular near target muscle.
- Rotate injection sites daily.
- 90° angle with short insulin needle.